Comparison of high-dose, short-term steroid and low-dose long-term steroid use in ARDS caused by COVID-19: Retrospective cohort study

Year 2022, Volume: 6 Issue: 3, 360 - 363, 01.03.2022

Suna Koç , İlke Küpeli

https://doi.org/10.28982/josam.1058849

Abstract

Background/Aim: Given the increasing incidence and mortality caused by coronavirus 2019 ( COVID-19) worldwide, beneficial and effective treatment for patients in the early pulmonary phase is still of great importance. Fifteen-day continuous hemodynamic, laboratory, and clinical courses of patients with acute respiratory distress syndrome (ARDS) due to COVID-19 who received short-term high-dose and long-term low-dose systemic methylprednisolone were compared.
Methods: Two hundred and two patients were reported to have ARDS due to COVID-19 in the intensive care unit between June 1, 2020 and February 1, 2021. The patients were divided into two groups: (1) short-term high-dose and (2) long-term low-dose systemic methylprednisolone. Age, gender, Acute Physiology and Chronic Health Evaluation (APACHE II) scores, steroid treatment protocol, intubation duration, length of stay (LOS), Neutrophil/Lymphocyte Ratio, C-reactive protein (CRP), procalcitonin, lactate levels, cytokine filter requirements, the prognosis, and total costs were obtained from their records.
Results: It was determined that elderly patients tended to be given low doses of steroids. No significant differences between the two treatment protocols in terms of other parameters were found. It was determined that high doses of steroids affected only CRP levels (P<0.05).
Conclusion: No differences in lactate, PCT levels, NLR, intubation and weaning times, hemoperfusion requirements, hospital stay, and prognosis between administration of different doses and durations of methylprednisolone for the treatment of COVID-19 ARDS were found.

Keywords

Methylprednisolone, COVID-19, ARDS, Prognosis

References

• 1. Rodríguez-Molinero A, Pérez-López C, Gálvez-Barrón C, Miñarro A, Rodríguez Gullello EA, Collado Pérez I, et al. (group of researchers for COVID-19 of the Consorci Sanitari de l’Alt Penedès i Garraf (CSAPG)). Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study. Med Clin (Engl Ed). 2021 Jan 10;156(1):7-12. doi: 10.1016/j.medcle.2020.08.001. Epub 2020 Nov 27. PMID: 33263084; PMCID: PMC7691846.
• 2. Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020 Dec 24;56(6):2002808. doi: 10.1183/13993003.02808-2020. PMID: 32943404; PMCID: PMC7758541.
• 3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-4. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16. PMID: 32192578; PMCID: PMC7270045.
• 4. Brown SM, Peltan ID, Barkauskas C, Rogers AJ, Kan V, Gelijns A, et al. What Does Acute Respiratory Distress Syndrome Mean during the COVID-19 Pandemic? Ann Am Thorac Soc. 2021 Dec;18(12):1948-50. doi: 10.1513/AnnalsATS.202105-534PS. PMID: 34288834; PMCID: PMC8641820.
• 5. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004 Nov;50(11):3408-17. doi: 10.1002/art.20583. PMID: 15529366.
• 6. Li J, Liao X, Zhou Y, Wang L, Yang H, Zhang W, et al. Comparison of Associations Between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis. Shock. 2021 Aug 1;56(2):215-28. doi: 10.1097/SHK.0000000000001738. PMID: 33555845.
• 7. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Oct 6;324(13):1330-41. doi: 10.1001/jama.2020.17023. PMID: 32876694; PMCID: PMC7489434.
• 8. Hu Y, Wang T, Hu Z, Wang X, Zhang Z, Li L, et al. Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience. Biomed Pharmacother. 2020 Oct;130:110529. doi: 10.1016/j.biopha.2020.110529. Epub 2020 Jul 28. PMID: 32736237; PMCID: PMC7386262.
• 9. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther. 2020 Apr 28;5(1):57. doi: 10.1038/s41392-020-0158-2. PMID: 32341331; PMCID: PMC7186116.
• 10. So C, Ro S, Murakami M, Imai R, Jinta T. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series. Respirol Case Rep. 2020 Jun 4;8(6):e00596. doi: 10.1002/rcr2.596. PMID: 32514354; PMCID: PMC7273438.